- Molecular NameParamethadione
- SynonymNA
- Weight157.169
- Drugbank_IDDB00617
- ACS_NO115-67-3
- Show 3D model
- LogP (experiment)0.763
- LogP (predicted, AB/LogP v2.0)0.32
- pkaN/A
- LogD (pH=7, predicted)0.32
- Solubility (experiment)8.4 mg/mL
- LogS (predicted, ACD/Labs)(ph=7)-0.92
- LogSw (predicted, AB/LogsW2.0)58.42
- Sw (mg/ml) (predicted, ACD/Labs)18.91
- No.of HBond Donors0
- No.of HBond Acceptors4
- No.of Rotatable Bonds1
- TPSA46.61
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn anticonvulsant in the oxazolidinedione class. It is associated with fetal trimethadione syndrome, which is also known as paramethadione syndrome.
- Absorption_valueN/A
- Absorption (description)Rapid via the digestive tract.
- Caco_2N/A
- BioavailabilityN/A
- Protein bindingN/A
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmPrimarily hepatic (mainly via cytochrome P450 isozyme 2C9), paramethadione is completely demethylated to 5-ethyl-5-methyl-2,4-oxazolidinedione, the active metabolite.
- Half lifeparamethadione about 16 h after a single dose, N-desmethylparamethadione about 7 to 14 days during chronic administration.
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySymptoms of overdose include clumsiness or unsteadiness, coma, severe dizziness, severe drowsiness, severe nausea, and problems with vision.
- LD50 (rat)N/A
- LD50 (mouse)N/A